How to break the vicious circle of antibiotic resistances?

Current Opinion in Critical Care

Volumn 14, Issue 5, 2008, Pages 587-592

  Leone, Marc ^a   Martin, Claude ^a  

^a HÔPITAL NORD   (France)

Author keywords

Antibiotics; De escalation; Infection; Sepsis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CIPROFLOXACIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL MENINGITIS; BACTERIAL PERITONITIS; BLOOD CULTURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; DRUG CHOICE; DRUG INDICATION; DRUG TREATMENT FAILURE; ECOLOGY; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHUMAN; PATIENT MONITORING; PSEUDOMONAS AERUGINOSA; RECURRENT INFECTION; REVIEW; SPLENECTOMY; SURGICAL PATIENT; TREATMENT DURATION; URINARY TRACT INFECTION; URINE CULTURE; WATCHFUL WAITING;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS;

EID: 55349089246     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32830f1deb     Document Type: Review

References (50)

1. Warren MM, Gibb AP, Walsh TS. Antibiotic prescription practice in an intensive care unit using twice-weekly collection of screening specimens: a prospective audit in a large UK teaching hospital. J Hosp Infect 2005; 59:90-95.
2. Osmon S, Warren D, Seiler SM, et al. The influence of infection on hospital mortality for patients requiring > 48 h of intensive care. Chest 2003; 124: 1021-1029.
3. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596.
4. Yu VL, Singh N. Excessive antimicrobial usage causes measurable harm to patients with suspected ventilator-associated pneumonia. Intensive Care Med 2004; 30:735-738.
5. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-888.
6. Depuydt P, Benoit D, Vogelaers D, et al. Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures. Intensive Care Med 2006; 32:1773-1781.
7. Alvarez-Lerma F, Alvarez B, Luque P, et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006; 10:R78.
8. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 2007; 35:379-385. In this paper, management of patients with VAP is based on a protocol taking into account the local ecology and the use of de-escalation.
9. Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003;31:462-467.
10. Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med 2006; 34:2758-2765.
11. Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129:862-869.
12. Brigden ML, Pattullo AL. Prevention and management of overwhelming postsplenectomy infection: an update. Crit Care Med 1999; 27:836-842.
13. Silber SH, Garrett C, Singh R, et al. Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. Chest 2003; 124:1798-1804.
14. Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic 'blind' bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143 (5 Pt 1):1121-1129.
15. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162 (2 Pt 1):505-511.
16. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-1423.
17. Lodise TP Jr, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51:3510-3515.
18. Leone M, Perrin AS, Granier I, et al. A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients. Intensive Care Med 2007; 33:726-729. The management of asymptomatic bacteriuria by a short course of antibiotics and urinary catheter change did not alter the outcomes in catheterized ICU patients as compared with controls.
19. Bouza E, Perez A, Munoz P, et al. Ventilator-associated pneumonia after heart surgery: a prospective analysis and the value of surveillance. Crit Care Med 2003; 31:1964-1970.
20. Hayon J, Figliolini C, Combes A, et al. Role of serial routine microbiologic culture results in the initial management of ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:41-46.
21. Blot S, Depuydt P, Vogelaers D, et al. Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit. Infect Control Hosp Epidemiol 2005; 26:575-579.
22. Michel F, Franceschini B, Berger P, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest 2005; 127:589-597.
23. Depuydt PO, Blot SI, Benoit DD, et al. Antimicrobial resistance in nosocomial blood stream infection associated with pneumonia and the value of regular surveillance cultures. Crit Care Med 2006; 34:653-659.
24. Combes A, Figliolini C, Trouillet JL, et al. Factors predicting ventilator-associated pneumonia recurrence. Crit Care Med 2003; 31:1102-1127.
25. Beardsley JR, Williamson JC, Johnson JW, et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006; 130:787-793.
26. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health care-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
27. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006; 355:2619-2630.
28. Gruson D, Hubert G, Vargas F, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003; 31:1908-1914.
29. Boselli E, Breilh D, Rimmele T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004; 30:989-991.
30. Albanese J, Leone M, Bruguerolle B, et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000; 44:1356-1358.
31. Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 2003; 31:2102-2106.
32. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45:2460-2467.
33. Boselli E, Breilh D, Rimmelé T, et al. Alveolar concentrations of piperacillin/ tazobactam in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 2008; 36:1500-1506. A target piperacillin serum concentration of at least 35-40 mg/l is probably required to provide alveolar concentrations exceeding the susceptibility breakpoint for Gram-negative bacteria (16 mg/l) during ventilator-associated pneumonia. In patients with no/mild renal failure, a continuous daily dose of piperacillin/tazobactam (16/2 g) allows reaching this target concentration, which might not be observed with 12/1.5g/day.
34. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-527.
35. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99.
36. Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 2006; 42 (Suppl 2):S72-S81.
37. Depuydt P, Blot S. Antibiotic therapy for ventilator-associated pneumonia: deescalation in the real world. Crit Care Med 2007; 35:632-633.
38. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-1115.
39. Soo Hoo GW, Wen YE, Nguyen TV, et al. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia Chest 2005; 128:2778-2787.
40. Giantsou E, Liratzopoulos N, Efraimidou E, et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007; 33:1533-1540. This study shows that de-escalation can be performed with safety for the patient outcomes.
41. Papazian L. How can earlier antibiotic efficacy be provided for ventilator-associated pneumonia without promoting bacterial resistance? Is initial monotherapy or a combination of antibiotics the right answer? Grit Care Med 2008; 36:994-995. An interesting editorial discussing the role of combination therapy.
42. Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006; 1 :CD003344.
43. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia; an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35:1888-1895. This study shows that combination therapy is useful in order to increase the likelihood of having an effective treatment against P. aeruginosa. However, if monotherapy is effective against P. aeruginosa, use of combination therapy does not improve clinical outcomes.
44. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 2005; 128:2706-2713.
45. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-2598.
46. Runyon BA, McHutchison JG, Antillen MR, et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991; 100:1737-1742.
47. Hedrick TL, Evans HL, Smith RL, et al. Can we define the ideal duration of antibiotic therapy? Surg Infect (Larchmt) 2006; 7:419-432.
48. Dupont H, Mentec H, Sollet JP, et al. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-362.
49. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-685.
50. Micek ST, Ward S, Fraser VJ, et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-1799.